Loading
JPXHealthcareBiotechnology
Latest quote
¥23.00
+¥1.00 · +4.55%
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Latest quote
¥23.00
+¥1.00 · +4.55%
Regular session · JST · Market data may be delayed.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Day range
Current ¥23.00
52-week range
Current ¥23.00
Regular session · JST · Market data may be delayed.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Day range
Current ¥23.00
52-week range
Current ¥23.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 808.53M JPY | 750.05M JPY | 610.12M JPY | 1.13B JPY | 1.15B JPY |
| Cost of goods sold | 794.57M JPY | 762.8M JPY | 787.84M JPY | 1.09B JPY | 1.04B JPY |
| Gross profit | 13.96M JPY | −12.76M JPY | −177.72M JPY | 41.69M JPY | 113.91M JPY |
| Research and development | 534.94M JPY | 491.11M JPY | 678.05M JPY | 716.46M JPY | 1.73B JPY |
| Selling, general, and administrative | 289.41M JPY | 294.07M JPY | 265.03M JPY | 431.64M JPY | 436.28M JPY |
| Operating expenses | 824.35M JPY | 785.18M JPY | 943.08M JPY | 1.15B JPY | 2.17B JPY |
| Interest income | 66K JPY | 751K JPY | — | 218K JPY | 146K JPY |
| Interest expense | 1.31M JPY | 1.2M JPY | 218K JPY | — | — |
| Depreciation and amortization | — | 797M JPY | 2K JPY | 16M JPY | 16.54M JPY |
| Operating income | −810.38M JPY | −797.94M JPY | −1.12B JPY | −1.11B JPY | −2.05B JPY |
| Net income | −910.64M JPY | −815.29M JPY | −1.29B JPY | −1.12B JPY | −2.57B JPY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 26, 2013 | 500:1 | — | — |
Stock split | Sep 27, 2004 | 3:1 | — | — |
Effective Sep 26, 2013
500:1
Effective Sep 27, 2004
3:1
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
